Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	5	8.7	57.4	(18.5-134.0)
Female	1	2.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	2	1.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)
Breast				
Male	0	0.3	nc	(nc-nc)
Female	33	30.0	110.1	(75.8-154.7)
Cervix Uteri				
Female	1	1.1	nc	(nc-nc)
Colon / Rectum				
Male	9	10.3	87.5	(39.9-166.0)
Female	10	8.2	122.3	(58.6-225.0)
Esophagus				
Male	2	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	3	4.7	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)
Larynx				
Male	2	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Leukemia				
Male	0	3.3	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	2.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Lung and Bronchus				
Male	10	15.8	63.4	(30.3-116.6)
Female	12	13.4	89.3	(46.1-155.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	11	5.7	193.3	(96.4-345.9)
Female	5	4.0	126.3	(40.7-294.7)
Multiple Myeloma				
Male	0	1.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	5.0	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	3.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
Ovary				
Female	3	2.7	nc	(nc-nc)
Pancreas				
Male	0	2.9	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)
Prostate				
Male	33	35.2	93.7	(64.5-131.7)
Stomach				
Male	1	2.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Testis				
Male	0	0.9	nc	(nc-nc)
Thyroid				
Male	1	1.9	nc	(nc-nc)
Female	8	5.6	143.9	(62.0-283.6)
Uteri Corpus and Uterus, NOS				
Female	3	6.9	nc	(nc-nc)
All Sites / Types				
Male	93	119.7	77.7	(62.7-95.2)
Female	97	98.5	98.5	(79.9-120.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	22	21.6	102.1	(63.9-154.5)
Female	9	8.1	110.6	(50.5-210.0)
Brain and Other Nervous System				
Male	2	4.0	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)
Breast				
Male	0	0.7	nc	(nc-nc)
Female	86	86.2	99.7	(79.8-123.2)
Cervix Uteri				
Female	2	3.2	nc	(nc-nc)
Colon / Rectum				
Male	22	25.6	85.9	(53.8-130.0)
Female	31	26.9	115.2	(78.2-163.5)
Esophagus				
Male	5	5.9	85.0	(27.4-198.3)
Female	2	1.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	1.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	11	11.8	93.2	(46.5-166.7)
Female	3	7.0	nc	(nc-nc)
Larynx				
Male	2	3.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Leukemia				
Male	6	7.9	75.7	(27.6-164.7)
Female	6	6.2	96.7	(35.3-210.6)
Liver and Intrahepatic Bile Ducts				
Male	4	6.9	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)
Lung and Bronchus				
Male	30	39.7	75.5	(50.9-107.7)
Female	41	41.7	98.4	(70.6-133.4)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	23	14.2	161.9	(102.6-243.0)
Female	18	11.6	154.7	(91.6-244.4)
Multiple Myeloma				
Male	3	3.9	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	13	12.5	104.4	(55.5-178.5)
Female	7	10.7	65.3	(26.2-134.6)
Oral Cavity & Pharynx				
Male	14	9.3	151.0	(82.5-253.4)
Female	1	4.4	nc	(nc-nc)
Ovary				
Female	10	7.9	126.1	(60.4-232.0)
Pancreas				
Male	6	7.1	85.1	(31.1-185.2)
Female	7	8.0	87.1	(34.9-179.5)
Prostate				
Male	72	85.8	83.9	(65.7-105.7)
Stomach				
Male	4	5.1	nc	(nc-nc)
Female	5	3.2	155.2	(50.0-362.2)
Testis				
Male	1	2.2	nc	(nc-nc)
Thyroid				
Male	5	4.8	104.5	(33.7-243.8)
Female	21	15.2	138.4	(85.7-211.6)
Uteri Corpus and Uterus, NOS				
Female	12	19.9	60.3	(31.1-105.4)
All Sites / Types				
Male	261	295.8	88.2	(77.9-99.6)
Female	297	296.9	100.0	(89.0-112.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	92	93.2	98.7	(79.6-121.1)
Female	33	36.7	89.9	(61.9-126.3)
Brain and Other Nervous System				
Male	22	17.0	129.6	(81.2-196.2)
Female	19	16.2	117.3	(70.6-183.2)
Breast				
Male	2	2.8	nc	(nc-nc)
Female	484	372.1	130.1	(118.7-142.2)
Cervix Uteri				
Female	11	13.6	80.7	(40.2-144.4)
Colon / Rectum				
Male	89	107.0	83.2	(66.8-102.4)
Female	105	121.2	86.7	(70.9-104.9)
Esophagus				
Male	12	23.8	50.4	(26.0-88.0)
Female	6	7.7	78.4	(28.6-170.7)
Hodgkin Lymphoma				
Male	3	7.3	nc	(nc-nc)
Female	4	6.8	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	47	47.0	100.0	(73.4-132.9)
Female	21	30.8	68.2	(42.2-104.3)
Larynx				
Male	9	13.7	65.7	(30.0-124.7)
Female	2	4.5	nc	(nc-nc)
Leukemia				
Male	39	34.6	112.6	(80.1-153.9)
Female	21	28.3	74.2	(45.9-113.4)
Liver and Intrahepatic Bile Ducts				
Male	26	27.2	95.8	(62.5-140.3)
Female	9	10.5	86.1	(39.3-163.4)
Lung and Bronchus				
Male	102	165.8	61.5	(50.2-74.7)
Female	154	186.5	82.6	(70.1-96.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	78	58.5	133.4	(105.4-166.5)
Female	61	51.7	118.0	(90.2-151.5)
Multiple Myeloma				
Male	23	15.8	145.6	(92.3-218.5)
Female	11	14.0	78.7	(39.2-140.8)
Non-Hodgkin Lymphoma				
Male	62	52.3	118.4	(90.8-151.8)
Female	52	48.0	108.4	(81.0-142.2)
Oral Cavity & Pharynx				
Male	37	36.3	101.8	(71.7-140.3)
Female	21	19.1	109.8	(67.9-167.8)
Ovary				
Female	41	34.7	118.2	(84.8-160.4)
Pancreas				
Male	32	29.7	107.6	(73.6-152.0)
Female	36	36.4	99.0	(69.3-137.1)
Prostate				
Male	386	336.5	114.7	(103.6-126.8)
Stomach				
Male	15	21.4	70.0	(39.2-115.5)
Female	10	14.6	68.4	(32.8-125.9)
Testis				
Male	14	11.0	127.1	(69.4-213.3)
Thyroid				
Male	32	18.9	169.0	(115.6-238.6)
Female	85	66.2	128.3	(102.5-158.7)
Uteri Corpus and Uterus, NOS				
Female	80	85.1	94.0	(74.5-117.0)
All Sites / Types				
Male	1211	1215.8	99.6	(94.1-105.4)
Female	1375	1310.6	104.9	(99.4-110.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	7	9.4	74.6	(29.9-153.7)
Female	3	2.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	3	2.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
Breast				
Male	1	0.3	nc	(nc-nc)
Female	44	31.1	141.5	(102.8-189.9)
Cervix Uteri				
Female	0	1.3	nc	(nc-nc)
Colon / Rectum				
Male	14	13.3	105.5	(57.7-177.1)
Female	10	7.5	133.7	(64.0-245.9)
Esophagus				
Male	2	3.1	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	10	7.1	140.8	(67.4-258.9)
Female	1	2.3	nc	(nc-nc)
Larynx				
Male	2	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Leukemia				
Male	5	4.2	120.0	(38.7-280.1)
Female	2	2.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	9	4.1	219.2	(100.0-416.1)
Female	0	0.7	nc	(nc-nc)
Lung and Bronchus				
Male	16	18.8	85.2	(48.7-138.3)
Female	10	12.2	82.0	(39.3-150.8)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	5	8.1	61.5	(19.8-143.6)
Female	7	4.2	168.4	(67.5-346.9)
Multiple Myeloma				
Male	2	1.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	10	7.0	142.0	(68.0-261.1)
Female	2	3.3	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	5.9	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)
Ovary				
Female	0	2.7	nc	(nc-nc)
Pancreas				
Male	4	3.4	nc	(nc-nc)
Female	5	2.1	234.0	(75.4-546.0)
Prostate				
Male	54	47.0	115.0	(86.4-150.0)
Stomach				
Male	2	2.5	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)
Testis				
Male	3	2.4	nc	(nc-nc)
Thyroid				
Male	4	3.6	nc	(nc-nc)
Female	8	6.4	124.1	(53.4-244.6)
Uteri Corpus and Uterus, NOS				
Female	11	7.0	156.6	(78.0-280.1)
All Sites / Types				
Male	162	158.6	102.1	(87.0-119.1)
Female	119	97.7	121.8	(100.9-145.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	19	15.1	126.2	(76.0-197.2)
Female	8	6.9	116.7	(50.2-229.9)
Brain and Other Nervous System				
Male	4	2.8	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)
Breast				
Male	1	0.4	nc	(nc-nc)
Female	50	62.1	80.6	(59.8-106.2)
Cervix Uteri				
Female	1	2.1	nc	(nc-nc)
Colon / Rectum				
Male	25	17.2	145.4	(94.1-214.6)
Female	29	22.4	129.6	(86.8-186.1)
Esophagus				
Male	12	3.7	326.2	(168.4-569.9)
Female	1	1.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	1.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	10	7.5	133.4	(63.9-245.4)
Female	3	5.4	nc	(nc-nc)
Larynx				
Male	3	2.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Leukemia				
Male	5	5.6	89.2	(28.7-208.0)
Female	5	5.1	97.2	(31.3-226.8)
Liver and Intrahepatic Bile Ducts				
Male	6	4.2	141.2	(51.6-307.4)
Female	0	1.9	nc	(nc-nc)
Lung and Bronchus				
Male	48	26.6	180.4	(133.0-239.2)
Female	53	34.3	154.4	(115.6-201.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	11	9.4	116.9	(58.3-209.2)
Female	6	8.8	68.3	(24.9-148.7)
Multiple Myeloma				
Male	4	2.5	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	8	8.5	93.8	(40.4-184.9)
Female	4	8.6	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	8	5.6	141.8	(61.0-279.4)
Female	1	3.3	nc	(nc-nc)
Ovary				
Female	2	5.9	nc	(nc-nc)
Pancreas				
Male	5	4.7	106.1	(34.2-247.7)
Female	10	6.8	146.5	(70.1-269.5)
Prostate				
Male	51	50.1	101.7	(75.7-133.7)
Stomach				
Male	3	3.4	nc	(nc-nc)
Female	7	2.7	255.6	(102.4-526.7)
Testis				
Male	2	2.1	nc	(nc-nc)
Thyroid				
Male	1	3.1	nc	(nc-nc)
Female	7	10.4	67.6	(27.1-139.3)
Uteri Corpus and Uterus, NOS				
Female	14	14.1	99.1	(54.1-166.2)
All Sites / Types				
Male	236	191.7	123.1	(107.9-139.9)
Female	217	229.1	94.7	(82.5-108.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	37	27.1	136.5	(96.1-188.2)
Female	18	11.3	159.3	(94.4-251.8)
Brain and Other Nervous System				
Male	5	5.6	88.9	(28.6-207.4)
Female	4	5.1	nc	(nc-nc)
Breast				
Male	5	0.8	589.1	(189.8-1374.7)
Female	118	114.1	103.5	(85.6-123.9)
Cervix Uteri				
Female	4	4.3	nc	(nc-nc)
Colon / Rectum				
Male	31	32.6	95.0	(64.5-134.8)
Female	46	38.2	120.5	(88.2-160.8)
Esophagus				
Male	6	7.3	82.4	(30.1-179.4)
Female	2	2.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	4	2.4	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	16	15.2	105.3	(60.1-171.0)
Female	5	9.3	53.6	(17.3-125.1)
Larynx				
Male	3	4.2	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
Leukemia				
Male	9	10.5	85.6	(39.1-162.5)
Female	12	8.9	134.2	(69.3-234.5)
Liver and Intrahepatic Bile Ducts				
Male	6	8.7	69.3	(25.3-150.9)
Female	4	3.2	nc	(nc-nc)
Lung and Bronchus				
Male	37	49.8	74.3	(52.3-102.5)
Female	51	55.6	91.8	(68.3-120.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	21	18.4	113.9	(70.5-174.1)
Female	13	16.0	81.2	(43.2-138.8)
Multiple Myeloma				
Male	3	4.8	nc	(nc-nc)
Female	3	4.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	13	16.3	79.9	(42.5-136.6)
Female	17	14.7	115.4	(67.2-184.8)
Oral Cavity & Pharynx				
Male	12	11.8	101.6	(52.5-177.6)
Female	8	5.9	136.7	(58.9-269.4)
Ovary				
Female	11	10.6	103.6	(51.6-185.3)
Pancreas				
Male	12	8.9	134.9	(69.6-235.7)
Female	16	11.3	142.0	(81.1-230.7)
Prostate				
Male	108	104.2	103.6	(85.0-125.1)
Stomach				
Male	5	6.4	77.9	(25.1-181.7)
Female	4	4.6	nc	(nc-nc)
Testis				
Male	7	3.8	182.8	(73.2-376.7)
Thyroid				
Male	10	6.5	153.2	(73.3-281.7)
Female	21	20.8	101.0	(62.5-154.4)
Uteri Corpus and Uterus, NOS				
Female	15	25.3	59.3	(33.2-97.9)
All Sites / Types				
Male	391	373.7	104.6	(94.5-115.5)
Female	416	402.4	103.4	(93.7-113.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	12	25.2	47.6	(24.6-83.2)
Female	8	8.6	92.8	(40.0-182.9)
Brain and Other Nervous System				
Male	8	5.5	144.5	(62.2-284.8)
Female	4	4.6	nc	(nc-nc)
Breast				
Male	0	0.8	nc	(nc-nc)
Female	104	103.5	100.5	(82.1-121.8)
Cervix Uteri				
Female	4	4.4	nc	(nc-nc)
Colon / Rectum				
Male	28	30.8	91.0	(60.5-131.6)
Female	34	29.0	117.3	(81.2-163.9)
Esophagus				
Male	6	7.3	82.1	(30.0-178.6)
Female	1	1.8	nc	(nc-nc)
Hodgkin Lymphoma				
Male	4	2.5	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	12	15.2	79.1	(40.8-138.1)
Female	8	8.1	98.6	(42.5-194.3)
Larynx				
Male	10	4.3	233.4	(111.7-429.2)
Female	0	1.2	nc	(nc-nc)
Leukemia				
Male	11	10.0	110.2	(54.9-197.1)
Female	6	7.3	81.7	(29.8-177.8)
Liver and Intrahepatic Bile Ducts				
Male	8	8.6	92.9	(40.0-183.2)
Female	0	2.6	nc	(nc-nc)
Lung and Bronchus				
Male	51	47.9	106.4	(79.3-140.0)
Female	42	45.5	92.4	(66.6-124.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	29	18.0	160.8	(107.6-230.9)
Female	14	14.7	95.3	(52.0-159.9)
Multiple Myeloma				
Male	1	4.6	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	10	15.7	63.6	(30.5-117.0)
Female	13	12.1	107.3	(57.1-183.5)
Oral Cavity & Pharynx				
Male	7	11.9	58.8	(23.5-121.1)
Female	6	5.0	119.5	(43.6-260.2)
Ovary				
Female	9	9.3	96.7	(44.1-183.6)
Pancreas				
Male	5	8.4	59.3	(19.1-138.4)
Female	11	8.5	129.9	(64.8-232.5)
Prostate				
Male	112	109.4	102.4	(84.3-123.2)
Stomach				
Male	3	6.1	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)
Testis				
Male	5	4.0	123.8	(39.9-288.9)
Thyroid				
Male	4	6.7	nc	(nc-nc)
Female	25	21.7	115.3	(74.6-170.2)
Uteri Corpus and Uterus, NOS				
Female	21	23.1	90.8	(56.2-138.7)
All Sites / Types				
Male	351	369.6	95.0	(85.3-105.4)
Female	339	345.9	98.0	(87.8-109.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	4	4.9	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	19	19.2	99.0	(59.6-154.6)
Cervix Uteri				
Female	0	0.7	nc	(nc-nc)
Colon / Rectum				
Male	8	6.3	127.8	(55.0-251.8)
Female	7	5.8	120.1	(48.1-247.5)
Esophagus				
Male	0	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	3	2.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)
Larynx				
Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	0	1.9	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Lung and Bronchus				
Male	5	9.0	55.3	(17.8-129.0)
Female	6	9.3	64.3	(23.5-139.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	3.5	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	3.0	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	2.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)
Ovary				
Female	4	1.7	nc	(nc-nc)
Pancreas				
Male	1	1.7	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)
Prostate				
Male	17	20.2	84.3	(49.1-135.0)
Stomach				
Male	1	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Testis				
Male	0	0.7	nc	(nc-nc)
Thyroid				
Male	1	1.3	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	4	4.4	nc	(nc-nc)
All Sites / Types				
Male	56	70.6	79.3	(59.9-103.0)
Female	54	66.1	81.6	(61.3-106.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	17	13.2	128.5	(74.8-205.7)
Female	9	4.8	186.9	(85.3-354.9)
Brain and Other Nervous System				
Male	5	2.8	176.2	(56.8-411.1)
Female	3	2.4	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	63	57.5	109.6	(84.2-140.2)
Cervix Uteri				
Female	3	2.3	nc	(nc-nc)
Colon / Rectum				
Male	25	16.3	153.4	(99.2-226.5)
Female	16	15.9	100.7	(57.5-163.6)
Esophagus				
Male	5	3.9	128.3	(41.3-299.3)
Female	0	1.0	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	1.2	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	6	8.1	74.2	(27.1-161.5)
Female	1	4.5	nc	(nc-nc)
Larynx				
Male	4	2.3	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)
Leukemia				
Male	7	5.1	136.2	(54.5-280.6)
Female	6	4.0	151.7	(55.4-330.1)
Liver and Intrahepatic Bile Ducts				
Male	1	4.7	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)
Lung and Bronchus				
Male	23	25.3	90.8	(57.6-136.3)
Female	17	25.9	65.6	(38.2-105.0)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	20	9.5	210.5	(128.5-325.1)
Female	11	7.8	141.1	(70.4-252.6)
Multiple Myeloma				
Male	2	2.4	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	11	8.3	132.8	(66.2-237.6)
Female	8	6.7	119.6	(51.5-235.7)
Oral Cavity & Pharynx				
Male	3	6.4	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)
Ovary				
Female	5	5.1	97.5	(31.4-227.5)
Pancreas				
Male	4	4.5	nc	(nc-nc)
Female	3	4.7	nc	(nc-nc)
Prostate				
Male	56	57.8	97.0	(73.2-125.9)
Stomach				
Male	3	3.2	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)
Testis				
Male	1	1.9	nc	(nc-nc)
Thyroid				
Male	2	3.5	nc	(nc-nc)
Female	12	11.1	108.0	(55.7-188.7)
Uteri Corpus and Uterus, NOS				
Female	11	13.1	83.9	(41.8-150.2)
All Sites / Types				
Male	218	194.7	112.0	(97.6-127.9)
Female	191	190.8	100.1	(86.4-115.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	22	28.7	76.6	(48.0-116.0)
Female	7	12.0	58.5	(23.4-120.5)
Brain and Other Nervous System				
Male	5	5.5	90.9	(29.3-212.2)
Female	9	5.5	164.5	(75.1-312.3)
Breast				
Male	2	0.9	nc	(nc-nc)
Female	122	121.0	100.8	(83.7-120.4)
Cervix Uteri				
Female	4	4.6	nc	(nc-nc)
Colon / Rectum				
Male	36	34.0	105.9	(74.2-146.6)
Female	28	40.1	69.9	(46.4-101.0)
Esophagus				
Male	11	7.9	139.3	(69.4-249.3)
Female	6	2.5	242.7	(88.6-528.2)
Hodgkin Lymphoma				
Male	3	2.3	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	15	15.7	95.3	(53.3-157.2)
Female	10	10.0	100.4	(48.1-184.6)
Larynx				
Male	3	4.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Leukemia				
Male	9	10.8	83.5	(38.1-158.5)
Female	12	9.4	128.1	(66.1-223.8)
Liver and Intrahepatic Bile Ducts				
Male	11	9.1	120.4	(60.0-215.5)
Female	0	3.4	nc	(nc-nc)
Lung and Bronchus				
Male	37	52.4	70.6	(49.7-97.3)
Female	59	59.5	99.1	(75.4-127.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	11	19.1	57.7	(28.8-103.3)
Female	11	17.8	61.7	(30.8-110.4)
Multiple Myeloma				
Male	4	5.0	nc	(nc-nc)
Female	6	4.6	131.8	(48.1-287.0)
Non-Hodgkin Lymphoma				
Male	16	16.8	95.3	(54.4-154.8)
Female	13	15.8	82.3	(43.8-140.8)
Oral Cavity & Pharynx				
Male	9	12.5	72.1	(32.9-136.8)
Female	9	6.3	142.9	(65.2-271.3)
Ovary				
Female	15	11.5	130.5	(73.0-215.2)
Pancreas				
Male	10	9.4	106.3	(50.9-195.5)
Female	16	11.9	134.5	(76.8-218.5)
Prostate				
Male	119	115.1	103.4	(85.7-123.7)
Stomach				
Male	3	6.8	nc	(nc-nc)
Female	4	4.9	nc	(nc-nc)
Testis				
Male	6	3.6	165.7	(60.5-360.7)
Thyroid				
Male	3	6.6	nc	(nc-nc)
Female	16	23.4	68.4	(39.1-111.1)
Uteri Corpus and Uterus, NOS				
Female	22	27.6	79.7	(49.9-120.7)
All Sites / Types				
Male	358	396.5	90.3	(81.2-100.1)
Female	400	430.9	92.8	(83.9-102.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	14	12.5	112.0	(61.2-188.0)
Female	6	4.8	124.5	(45.5-271.0)
Brain and Other Nervous System				
Male	4	2.9	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	54	57.2	94.5	(71.0-123.3)
Cervix Uteri				
Female	2	2.3	nc	(nc-nc)
Colon / Rectum				
Male	15	15.8	94.7	(53.0-156.2)
Female	24	16.1	149.1	(95.5-221.8)
Esophagus				
Male	2	3.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.2	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	5	7.8	64.1	(20.7-149.7)
Female	2	4.5	nc	(nc-nc)
Larynx				
Male	3	2.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Leukemia				
Male	7	5.1	137.3	(55.0-283.0)
Female	1	4.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	4.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)
Lung and Bronchus				
Male	19	23.5	81.0	(48.7-126.5)
Female	13	25.6	50.9	(27.1-87.0)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	4	9.2	nc	(nc-nc)
Female	9	7.8	115.6	(52.8-219.5)
Multiple Myeloma				
Male	2	2.4	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	7	8.1	86.5	(34.7-178.3)
Female	5	6.7	74.9	(24.1-174.9)
Oral Cavity & Pharynx				
Male	3	6.3	nc	(nc-nc)
Female	5	2.8	180.8	(58.3-422.0)
Ovary				
Female	3	5.1	nc	(nc-nc)
Pancreas				
Male	6	4.3	141.0	(51.5-306.9)
Female	4	4.7	nc	(nc-nc)
Prostate				
Male	63	53.5	117.7	(90.5-150.6)
Stomach				
Male	4	3.1	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)
Testis				
Male	0	2.0	nc	(nc-nc)
Thyroid				
Male	3	3.5	nc	(nc-nc)
Female	5	11.1	45.0	(14.5-104.9)
Uteri Corpus and Uterus, NOS				
Female	11	12.9	85.5	(42.6-152.9)
All Sites / Types				
Male	175	185.5	94.4	(80.9-109.4)
Female	170	190.1	89.4	(76.5-103.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	20	14.0	143.1	(87.4-221.0)
Female	7	6.1	115.6	(46.3-238.2)
Brain and Other Nervous System				
Male	0	2.9	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)
Breast				
Male	1	0.5	nc	(nc-nc)
Female	65	60.4	107.7	(83.1-137.2)
Cervix Uteri				
Female	2	2.3	nc	(nc-nc)
Colon / Rectum				
Male	15	17.2	87.4	(48.9-144.2)
Female	19	20.4	93.2	(56.1-145.6)
Esophagus				
Male	8	3.8	212.1	(91.3-418.0)
Female	1	1.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	1.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	12	7.8	153.1	(79.0-267.5)
Female	1	5.0	nc	(nc-nc)
Larynx				
Male	1	2.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Leukemia				
Male	10	5.6	179.6	(86.0-330.3)
Female	2	4.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	7	4.4	157.9	(63.3-325.4)
Female	3	1.7	nc	(nc-nc)
Lung and Bronchus				
Male	25	25.1	99.5	(64.4-146.9)
Female	29	29.7	97.5	(65.3-140.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	5	9.5	52.9	(17.0-123.4)
Female	7	8.6	81.5	(32.6-167.9)
Multiple Myeloma				
Male	7	2.4	286.7	(114.8-590.7)
Female	3	2.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	5	8.4	59.4	(19.1-138.5)
Female	9	7.9	114.2	(52.1-216.9)
Oral Cavity & Pharynx				
Male	9	6.2	144.9	(66.1-275.0)
Female	6	3.1	192.2	(70.2-418.4)
Ovary				
Female	9	5.6	159.3	(72.7-302.4)
Pancreas				
Male	4	4.6	nc	(nc-nc)
Female	7	6.0	116.0	(46.5-238.9)
Prostate				
Male	66	54.1	121.9	(94.3-155.1)
Stomach				
Male	0	3.4	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)
Testis				
Male	3	2.1	nc	(nc-nc)
Thyroid				
Male	3	3.4	nc	(nc-nc)
Female	13	11.2	116.2	(61.8-198.7)
Uteri Corpus and Uterus, NOS				
Female	14	13.4	104.5	(57.1-175.3)
All Sites / Types				
Male	223	193.8	115.1	(100.4-131.2)
Female	219	214.7	102.0	(88.9-116.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	3	3.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	15	13.8	108.6	(60.7-179.1)
Cervix Uteri				
Female	0	0.5	nc	(nc-nc)
Colon / Rectum				
Male	4	4.3	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)
Esophagus				
Male	1	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	2	2.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)
Larynx				
Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	1	1.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Lung and Bronchus				
Male	3	6.7	nc	(nc-nc)
Female	4	6.6	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	2.5	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)
Multiple Myeloma				
Male	1	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	2.1	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	1.7	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)
Ovary				
Female	1	1.3	nc	(nc-nc)
Pancreas				
Male	1	1.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)
Prostate				
Male	16	16.3	98.4	(56.2-159.9)
Stomach				
Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Testis				
Male	1	0.4	nc	(nc-nc)
Thyroid				
Male	0	0.9	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	6	3.2	187.1	(68.3-407.2)
All Sites / Types				
Male	39	52.1	74.9	(53.3-102.4)
Female	43	47.0	91.4	(66.2-123.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	10	14.0	71.3	(34.1-131.1)
Female	6	5.4	110.7	(40.4-240.9)
Brain and Other Nervous System				
Male	3	3.5	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)
Breast				
Male	0	0.5	nc	(nc-nc)
Female	64	65.4	97.9	(75.4-125.0)
Cervix Uteri				
Female	2	2.8	nc	(nc-nc)
Colon / Rectum				
Male	28	17.9	156.7	(104.1-226.4)
Female	24	18.2	132.0	(84.6-196.5)
Esophagus				
Male	7	4.3	164.1	(65.7-338.1)
Female	2	1.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	1.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	9	9.1	99.0	(45.2-188.0)
Female	7	5.1	136.7	(54.8-281.7)
Larynx				
Male	3	2.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Leukemia				
Male	3	5.9	nc	(nc-nc)
Female	6	4.7	127.8	(46.7-278.2)
Liver and Intrahepatic Bile Ducts				
Male	10	5.3	187.6	(89.8-345.0)
Female	0	1.6	nc	(nc-nc)
Lung and Bronchus				
Male	28	26.7	104.8	(69.6-151.5)
Female	27	28.5	94.8	(62.5-138.0)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	8	10.7	74.5	(32.1-146.8)
Female	16	9.4	169.9	(97.1-275.9)
Multiple Myeloma				
Male	5	2.7	185.5	(59.8-432.9)
Female	3	2.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	7	9.4	74.2	(29.7-152.8)
Female	10	7.7	130.2	(62.3-239.5)
Oral Cavity & Pharynx				
Male	6	7.5	80.4	(29.4-175.1)
Female	3	3.2	nc	(nc-nc)
Ovary				
Female	8	5.9	134.8	(58.0-265.6)
Pancreas				
Male	6	4.8	124.9	(45.6-271.9)
Female	3	5.3	nc	(nc-nc)
Prostate				
Male	73	62.6	116.5	(91.3-146.5)
Stomach				
Male	3	3.5	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)
Testis				
Male	5	2.7	187.8	(60.5-438.2)
Thyroid				
Male	7	4.3	164.1	(65.7-338.1)
Female	15	13.9	107.8	(60.3-177.9)
Uteri Corpus and Uterus, NOS				
Female	16	14.7	108.7	(62.1-176.5)
All Sites / Types				
Male	236	214.7	109.9	(96.3-124.9)
Female	229	218.9	104.6	(91.5-119.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	12	12.7	94.7	(48.9-165.4)
Female	0	4.4	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	2.4	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	37	46.9	79.0	(55.6-108.8)
Cervix Uteri				
Female	1	1.7	nc	(nc-nc)
Colon / Rectum				
Male	19	14.9	127.6	(76.8-199.3)
Female	13	14.5	89.4	(47.6-152.9)
Esophagus				
Male	1	3.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.9	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	8	7.0	114.1	(49.1-224.9)
Female	4	3.8	nc	(nc-nc)
Larynx				
Male	2	2.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Leukemia				
Male	4	4.6	nc	(nc-nc)
Female	6	3.4	175.1	(63.9-381.2)
Liver and Intrahepatic Bile Ducts				
Male	0	4.1	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)
Lung and Bronchus				
Male	15	23.7	63.2	(35.3-104.2)
Female	19	22.5	84.6	(50.9-132.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	10	8.3	120.1	(57.5-220.8)
Female	10	6.2	160.1	(76.7-294.5)
Multiple Myeloma				
Male	1	2.2	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	7.3	nc	(nc-nc)
Female	7	5.8	120.8	(48.4-248.9)
Oral Cavity & Pharynx				
Male	6	5.5	108.2	(39.5-235.5)
Female	5	2.4	212.0	(68.3-494.6)
Ovary				
Female	8	4.3	186.3	(80.2-367.1)
Pancreas				
Male	2	4.2	nc	(nc-nc)
Female	6	4.3	138.2	(50.5-300.7)
Prostate				
Male	48	51.5	93.3	(68.8-123.7)
Stomach				
Male	2	3.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Testis				
Male	0	1.2	nc	(nc-nc)
Thyroid				
Male	3	2.8	nc	(nc-nc)
Female	8	8.1	98.8	(42.5-194.7)
Uteri Corpus and Uterus, NOS				
Female	11	10.8	102.2	(50.9-182.9)
All Sites / Types				
Male	147	174.9	84.0	(71.0-98.8)
Female	158	160.7	98.3	(83.6-114.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	25	34.5	72.4	(46.9-106.9)
Female	15	13.9	107.8	(60.3-177.8)
Brain and Other Nervous System				
Male	10	6.3	159.0	(76.1-292.4)
Female	9	5.8	155.1	(70.8-294.5)
Breast				
Male	2	1.0	nc	(nc-nc)
Female	149	131.3	113.5	(96.0-133.2)
Cervix Uteri				
Female	6	4.8	126.1	(46.0-274.4)
Colon / Rectum				
Male	44	39.5	111.4	(81.0-149.6)
Female	46	45.7	100.7	(73.7-134.4)
Esophagus				
Male	12	8.6	140.2	(72.3-244.8)
Female	3	2.9	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	2.7	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	21	17.5	120.3	(74.4-183.9)
Female	14	11.2	124.8	(68.2-209.4)
Larynx				
Male	6	4.9	121.3	(44.3-264.0)
Female	2	1.6	nc	(nc-nc)
Leukemia				
Male	11	12.7	86.7	(43.2-155.1)
Female	7	10.5	66.6	(26.7-137.3)
Liver and Intrahepatic Bile Ducts				
Male	11	9.7	113.3	(56.5-202.7)
Female	2	3.9	nc	(nc-nc)
Lung and Bronchus				
Male	81	61.2	132.3	(105.0-164.4)
Female	84	70.1	119.9	(95.6-148.4)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	23	21.7	105.8	(67.0-158.8)
Female	24	18.4	130.2	(83.4-193.7)
Multiple Myeloma				
Male	6	5.8	104.0	(38.0-226.4)
Female	5	5.2	95.7	(30.8-223.2)
Non-Hodgkin Lymphoma				
Male	30	19.4	154.4	(104.1-220.4)
Female	18	17.7	101.6	(60.2-160.5)
Oral Cavity & Pharynx				
Male	14	13.1	107.2	(58.6-179.9)
Female	5	6.9	72.4	(23.3-169.0)
Ovary				
Female	22	12.4	177.9	(111.5-269.4)
Pancreas				
Male	13	10.9	119.1	(63.3-203.6)
Female	16	13.8	115.6	(66.0-187.7)
Prostate				
Male	100	119.1	83.9	(68.3-102.1)
Stomach				
Male	11	7.9	138.6	(69.1-248.0)
Female	8	5.6	143.6	(61.8-283.0)
Testis				
Male	8	4.5	176.5	(76.0-347.7)
Thyroid				
Male	6	7.2	83.5	(30.5-181.8)
Female	25	22.7	110.2	(71.3-162.7)
Uteri Corpus and Uterus, NOS				
Female	32	29.7	107.7	(73.6-152.0)
All Sites / Types				
Male	479	443.9	107.9	(98.4-118.0)
Female	543	476.0	114.1	(104.7-124.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	4	4.3	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.7	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
Breast				
Male	1	0.1	nc	(nc-nc)
Female	14	19.5	71.9	(39.3-120.6)
Cervix Uteri				
Female	0	0.7	nc	(nc-nc)
Colon / Rectum				
Male	4	4.8	nc	(nc-nc)
Female	7	6.4	108.6	(43.5-223.8)
Esophagus				
Male	2	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	2.1	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)
Larynx				
Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	1	1.5	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	3	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Lung and Bronchus				
Male	5	7.7	65.2	(21.0-152.1)
Female	8	10.1	79.2	(34.1-156.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	7	2.6	270.2	(108.2-556.7)
Female	2	2.7	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	2.3	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	1.5	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)
Ovary				
Female	1	1.8	nc	(nc-nc)
Pancreas				
Male	2	1.3	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)
Prostate				
Male	23	14.7	156.7	(99.3-235.1)
Stomach				
Male	0	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Testis				
Male	0	0.4	nc	(nc-nc)
Thyroid				
Male	0	0.8	nc	(nc-nc)
Female	5	3.3	150.4	(48.5-351.0)
Uteri Corpus and Uterus, NOS				
Female	6	4.5	133.6	(48.8-290.7)
All Sites / Types				
Male	66	53.8	122.6	(94.8-156.0)
Female	64	69.1	92.6	(71.3-118.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	2	1.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Breast				
Male	1	0.1	nc	(nc-nc)
Female	7	7.0	99.7	(39.9-205.4)
Cervix Uteri				
Female	0	0.3	nc	(nc-nc)
Colon / Rectum				
Male	0	2.1	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Esophagus				
Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	2	1.1	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)
Larynx				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	3	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	2	3.1	nc	(nc-nc)
Female	0	2.8	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	1.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	1.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	0.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Ovary				
Female	0	0.6	nc	(nc-nc)
Pancreas				
Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Prostate				
Male	9	7.4	121.7	(55.5-231.1)
Stomach				
Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	0	0.3	nc	(nc-nc)
Thyroid				
Male	2	0.5	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	1	1.6	nc	(nc-nc)
All Sites / Types				
Male	28	24.7	113.5	(75.4-164.0)
Female	19	22.2	85.7	(51.6-133.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	13	7.6	170.2	(90.5-291.1)
Female	3	3.1	nc	(nc-nc)
Brain and Other Nervous System				
Male	3	1.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	32	33.0	96.9	(66.3-136.8)
Cervix Uteri				
Female	1	1.2	nc	(nc-nc)
Colon / Rectum				
Male	13	9.1	143.0	(76.1-244.6)
Female	4	10.2	nc	(nc-nc)
Esophagus				
Male	1	2.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	4	4.3	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)
Larynx				
Male	0	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Leukemia				
Male	1	2.9	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	3	2.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Lung and Bronchus				
Male	15	14.3	104.9	(58.7-173.0)
Female	15	16.4	91.4	(51.1-150.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	3	5.2	nc	(nc-nc)
Female	1	4.6	nc	(nc-nc)
Multiple Myeloma				
Male	1	1.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	6	4.5	133.3	(48.7-290.1)
Female	3	4.2	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	3	3.5	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Ovary				
Female	1	3.0	nc	(nc-nc)
Pancreas				
Male	0	2.6	nc	(nc-nc)
Female	0	3.1	nc	(nc-nc)
Prostate				
Male	31	31.8	97.4	(66.2-138.3)
Stomach				
Male	1	1.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Testis				
Male	0	1.0	nc	(nc-nc)
Thyroid				
Male	0	1.8	nc	(nc-nc)
Female	7	6.0	116.0	(46.5-239.1)
Uteri Corpus and Uterus, NOS				
Female	14	7.6	183.1	(100.0-307.2)
All Sites / Types				
Male	104	108.0	96.3	(78.7-116.7)
Female	95	114.8	82.8	(67.0-101.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	19	16.5	115.3	(69.4-180.1)
Female	6	5.6	107.0	(39.1-232.9)
Brain and Other Nervous System				
Male	2	2.2	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)
Breast				
Male	0	0.5	nc	(nc-nc)
Female	71	45.1	157.6	(123.1-198.8)
Cervix Uteri				
Female	0	1.2	nc	(nc-nc)
Colon / Rectum				
Male	14	17.6	79.4	(43.3-133.2)
Female	21	17.7	118.7	(73.4-181.4)
Esophagus				
Male	3	4.0	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	7	7.3	95.9	(38.4-197.6)
Female	1	4.1	nc	(nc-nc)
Larynx				
Male	4	2.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Leukemia				
Male	7	5.3	132.4	(53.1-272.9)
Female	3	3.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	4.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Lung and Bronchus				
Male	12	29.6	40.5	(20.9-70.8)
Female	19	28.3	67.0	(40.3-104.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	16	9.2	174.1	(99.5-282.8)
Female	14	5.9	238.0	(130.0-399.3)
Multiple Myeloma				
Male	1	2.7	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	7	7.9	88.1	(35.3-181.5)
Female	8	6.7	119.8	(51.6-236.2)
Oral Cavity & Pharynx				
Male	4	5.3	nc	(nc-nc)
Female	5	2.5	199.7	(64.4-466.1)
Ovary				
Female	4	4.4	nc	(nc-nc)
Pancreas				
Male	1	5.2	nc	(nc-nc)
Female	2	5.6	nc	(nc-nc)
Prostate				
Male	64	56.9	112.5	(86.6-143.6)
Stomach				
Male	1	3.6	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)
Testis				
Male	1	0.6	nc	(nc-nc)
Thyroid				
Male	0	2.4	nc	(nc-nc)
Female	3	5.5	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	17	10.7	159.6	(92.9-255.5)
All Sites / Types				
Male	186	199.1	93.4	(80.5-107.9)
Female	200	172.0	116.3	(100.7-133.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	1.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	6	7.1	84.7	(30.9-184.3)
Cervix Uteri				
Female	0	0.3	nc	(nc-nc)
Colon / Rectum				
Male	2	2.1	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)
Esophagus				
Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	1.0	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Larynx				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	5	3.3	151.0	(48.7-352.5)
Female	3	3.4	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	1.2	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	1.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Ovary				
Female	2	0.6	nc	(nc-nc)
Pancreas				
Male	1	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Prostate				
Male	13	7.7	168.0	(89.4-287.4)
Stomach				
Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	0	0.2	nc	(nc-nc)
Thyroid				
Male	0	0.4	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	1	1.7	nc	(nc-nc)
All Sites / Types				
Male	30	25.0	120.2	(81.1-171.6)
Female	20	23.6	84.7	(51.7-130.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	16	13.9	115.2	(65.8-187.2)
Female	7	4.5	154.9	(62.1-319.2)
Brain and Other Nervous System				
Male	4	2.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)
Breast				
Male	1	0.4	nc	(nc-nc)
Female	48	53.4	89.9	(66.3-119.2)
Cervix Uteri				
Female	0	2.2	nc	(nc-nc)
Colon / Rectum				
Male	8	17.1	46.9	(20.2-92.3)
Female	12	15.0	80.2	(41.4-140.0)
Esophagus				
Male	5	4.1	122.5	(39.5-285.9)
Female	0	1.0	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.2	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	4	8.2	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)
Larynx				
Male	2	2.4	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)
Leukemia				
Male	5	5.5	91.7	(29.6-214.1)
Female	2	3.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	4	4.9	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)
Lung and Bronchus				
Male	40	26.1	153.3	(109.5-208.7)
Female	30	24.4	123.1	(83.0-175.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	6	9.8	61.2	(22.3-133.2)
Female	7	7.4	94.1	(37.7-194.0)
Multiple Myeloma				
Male	1	2.6	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	10	8.5	117.3	(56.2-215.7)
Female	7	6.3	111.2	(44.5-229.0)
Oral Cavity & Pharynx				
Male	9	6.7	134.6	(61.4-255.5)
Female	1	2.6	nc	(nc-nc)
Ovary				
Female	3	4.8	nc	(nc-nc)
Pancreas				
Male	2	4.7	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)
Prostate				
Male	45	60.6	74.2	(54.1-99.3)
Stomach				
Male	2	3.4	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)
Testis				
Male	3	1.9	nc	(nc-nc)
Thyroid				
Male	7	3.6	197.1	(79.0-406.1)
Female	3	10.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	13	12.1	107.3	(57.1-183.5)
All Sites / Types				
Male	189	203.0	93.1	(80.3-107.4)
Female	166	178.9	92.8	(79.2-108.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	19	15.8	120.3	(72.4-187.9)
Female	5	5.4	92.0	(29.6-214.6)
Brain and Other Nervous System				
Male	0	2.9	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)
Breast				
Male	0	0.5	nc	(nc-nc)
Female	50	53.9	92.8	(68.9-122.3)
Cervix Uteri				
Female	1	2.0	nc	(nc-nc)
Colon / Rectum				
Male	10	18.3	54.5	(26.1-100.3)
Female	13	18.0	72.1	(38.4-123.3)
Esophagus				
Male	2	3.9	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	7	7.8	89.2	(35.7-183.8)
Female	2	4.5	nc	(nc-nc)
Larynx				
Male	3	2.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Leukemia				
Male	4	6.0	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	3	4.5	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Lung and Bronchus				
Male	29	27.3	106.4	(71.2-152.8)
Female	23	27.4	84.0	(53.2-126.0)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	10	9.8	102.0	(48.8-187.6)
Female	11	7.5	146.2	(72.9-261.5)
Multiple Myeloma				
Male	0	2.6	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	5	8.9	56.3	(18.1-131.4)
Female	8	7.0	113.6	(48.9-223.9)
Oral Cavity & Pharynx				
Male	8	6.1	131.7	(56.7-259.5)
Female	1	2.8	nc	(nc-nc)
Ovary				
Female	2	5.0	nc	(nc-nc)
Pancreas				
Male	5	5.0	100.1	(32.3-233.6)
Female	6	5.4	111.1	(40.6-241.9)
Prostate				
Male	40	53.3	75.0	(53.6-102.2)
Stomach				
Male	4	3.7	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)
Testis				
Male	2	1.9	nc	(nc-nc)
Thyroid				
Male	4	3.2	nc	(nc-nc)
Female	9	9.6	93.8	(42.8-178.0)
Uteri Corpus and Uterus, NOS				
Female	15	12.1	123.9	(69.3-204.3)
All Sites / Types				
Male	171	201.3	85.0	(72.7-98.7)
Female	168	191.4	87.8	(75.0-102.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	5	6.6	75.9	(24.5-177.2)
Female	1	1.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	2	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	21	18.3	114.9	(71.1-175.7)
Cervix Uteri				
Female	0	0.7	nc	(nc-nc)
Colon / Rectum				
Male	3	7.3	nc	(nc-nc)
Female	7	5.4	130.6	(52.3-269.1)
Esophagus				
Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	3.3	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)
Larynx				
Male	3	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	1	2.4	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	1.9	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)
Lung and Bronchus				
Male	5	11.9	41.9	(13.5-97.7)
Female	5	8.8	56.8	(18.3-132.4)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	3	4.0	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)
Multiple Myeloma				
Male	0	1.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	2	3.6	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	2.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Ovary				
Female	3	1.7	nc	(nc-nc)
Pancreas				
Male	1	2.1	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)
Prostate				
Male	19	25.3	75.2	(45.3-117.5)
Stomach				
Male	2	1.5	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)
Testis				
Male	0	0.6	nc	(nc-nc)
Thyroid				
Male	4	1.3	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	5	4.2	119.2	(38.4-278.1)
All Sites / Types				
Male	57	86.4	66.0	(50.0-85.5)
Female	55	62.3	88.3	(66.5-114.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	70	67.7	103.4	(80.6-130.6)
Female	33	26.8	123.0	(84.7-172.8)
Brain and Other Nervous System				
Male	15	11.7	128.6	(71.9-212.1)
Female	6	10.8	55.3	(20.2-120.4)
Breast				
Male	4	2.0	nc	(nc-nc)
Female	241	251.5	95.8	(84.1-108.7)
Cervix Uteri				
Female	7	8.7	80.6	(32.3-166.1)
Colon / Rectum				
Male	84	76.3	110.0	(87.8-136.2)
Female	95	87.6	108.5	(87.8-132.6)
Esophagus				
Male	11	17.0	64.7	(32.3-115.9)
Female	4	5.6	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	4.6	nc	(nc-nc)
Female	6	4.1	145.8	(53.3-317.4)
Kidney & Renal Pelvis				
Male	46	33.3	138.0	(101.0-184.0)
Female	31	21.5	144.1	(97.9-204.6)
Larynx				
Male	11	9.7	113.3	(56.5-202.8)
Female	3	3.1	nc	(nc-nc)
Leukemia				
Male	30	24.3	123.7	(83.4-176.6)
Female	29	19.8	146.2	(97.9-209.9)
Liver and Intrahepatic Bile Ducts				
Male	23	19.3	119.2	(75.6-178.9)
Female	7	7.4	94.2	(37.7-194.0)
Lung and Bronchus				
Male	138	120.4	114.6	(96.3-135.4)
Female	176	135.7	129.7	(111.3-150.4)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	36	41.6	86.5	(60.6-119.8)
Female	46	34.5	133.3	(97.6-177.8)
Multiple Myeloma				
Male	10	11.3	88.2	(42.2-162.2)
Female	16	10.1	158.7	(90.6-257.7)
Non-Hodgkin Lymphoma				
Male	49	36.8	133.0	(98.4-175.8)
Female	55	33.9	162.1	(122.1-211.0)
Oral Cavity & Pharynx				
Male	31	25.5	121.5	(82.5-172.5)
Female	11	13.2	83.1	(41.4-148.8)
Ovary				
Female	22	23.6	93.1	(58.3-140.9)
Pancreas				
Male	22	21.6	101.9	(63.8-154.2)
Female	33	26.6	123.8	(85.2-173.9)
Prostate				
Male	263	237.4	110.8	(97.8-125.0)
Stomach				
Male	17	15.3	111.2	(64.7-178.0)
Female	8	10.6	75.1	(32.4-148.1)
Testis				
Male	9	6.7	133.4	(60.9-253.3)
Thyroid				
Male	13	13.0	100.1	(53.2-171.2)
Female	44	41.2	106.8	(77.6-143.3)
Uteri Corpus and Uterus, NOS				
Female	68	57.5	118.4	(91.9-150.0)
All Sites / Types				
Male	982	863.5	113.7	(106.7-121.1)
Female	1029	909.9	113.1	(106.3-120.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	1.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	5	6.5	77.5	(25.0-180.9)
Cervix Uteri				
Female	0	0.2	nc	(nc-nc)
Colon / Rectum				
Male	2	2.0	nc	(nc-nc)
Female	4	1.7	nc	(nc-nc)
Esophagus				
Male	0	0.5	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Larynx				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	1	3.2	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	1.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Ovary				
Female	0	0.6	nc	(nc-nc)
Pancreas				
Male	1	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Prostate				
Male	10	7.2	139.4	(66.7-256.4)
Stomach				
Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	0	0.1	nc	(nc-nc)
Thyroid				
Male	1	0.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	0	1.6	nc	(nc-nc)
All Sites / Types				
Male	19	23.7	80.1	(48.2-125.1)
Female	17	21.2	80.3	(46.8-128.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	19	15.6	121.5	(73.1-189.7)
Female	3	5.3	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	3.7	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)
Breast				
Male	0	0.5	nc	(nc-nc)
Female	84	67.8	123.8	(98.8-153.3)
Cervix Uteri				
Female	2	2.8	nc	(nc-nc)
Colon / Rectum				
Male	22	19.6	112.5	(70.5-170.3)
Female	18	17.5	102.7	(60.8-162.3)
Esophagus				
Male	4	4.7	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	1.5	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	10	9.9	101.0	(48.3-185.7)
Female	5	5.3	94.8	(30.5-221.2)
Larynx				
Male	1	2.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Leukemia				
Male	8	6.3	126.7	(54.6-249.6)
Female	3	4.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	8	5.7	139.6	(60.1-275.2)
Female	0	1.7	nc	(nc-nc)
Lung and Bronchus				
Male	39	29.9	130.4	(92.7-178.3)
Female	45	29.5	152.8	(111.4-204.4)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	16	11.6	138.2	(79.0-224.5)
Female	8	9.3	86.2	(37.1-169.8)
Multiple Myeloma				
Male	4	2.9	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	14	10.1	138.0	(75.4-231.6)
Female	10	7.7	130.7	(62.6-240.3)
Oral Cavity & Pharynx				
Male	7	7.9	88.3	(35.4-181.9)
Female	2	3.2	nc	(nc-nc)
Ovary				
Female	7	6.0	116.3	(46.6-239.6)
Pancreas				
Male	4	5.3	nc	(nc-nc)
Female	5	5.2	96.4	(31.1-224.9)
Prostate				
Male	86	68.4	125.7	(100.5-155.2)
Stomach				
Male	2	3.9	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)
Testis				
Male	1	2.4	nc	(nc-nc)
Thyroid				
Male	4	4.4	nc	(nc-nc)
Female	19	13.8	137.9	(83.0-215.3)
Uteri Corpus and Uterus, NOS				
Female	17	15.7	108.5	(63.2-173.8)
All Sites / Types				
Male	263	233.8	112.5	(99.3-127.0)
Female	256	221.4	115.6	(101.9-130.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	12	8.4	143.6	(74.1-250.8)
Female	1	3.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	4	2.2	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)
Breast				
Male	0	0.3	nc	(nc-nc)
Female	51	41.5	122.8	(91.4-161.5)
Cervix Uteri				
Female	3	1.7	nc	(nc-nc)
Colon / Rectum				
Male	7	10.9	64.2	(25.7-132.3)
Female	10	10.8	93.0	(44.5-171.1)
Esophagus				
Male	3	2.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	3	5.7	nc	(nc-nc)
Female	5	3.2	157.5	(50.8-367.5)
Larynx				
Male	0	1.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)
Leukemia				
Male	6	3.6	168.7	(61.6-367.3)
Female	3	2.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	3.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Lung and Bronchus				
Male	17	16.4	103.8	(60.5-166.3)
Female	21	17.4	120.7	(74.7-184.5)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	5	6.6	75.4	(24.3-176.0)
Female	3	5.7	nc	(nc-nc)
Multiple Myeloma				
Male	2	1.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	8	5.8	139.1	(59.9-274.0)
Female	5	4.6	108.2	(34.9-252.5)
Oral Cavity & Pharynx				
Male	3	4.8	nc	(nc-nc)
Female	6	2.0	306.1	(111.8-666.2)
Ovary				
Female	1	3.7	nc	(nc-nc)
Pancreas				
Male	1	2.9	nc	(nc-nc)
Female	6	3.1	192.3	(70.2-418.5)
Prostate				
Male	36	40.2	89.6	(62.8-124.1)
Stomach				
Male	5	2.1	234.4	(75.5-547.0)
Female	0	1.2	nc	(nc-nc)
Testis				
Male	0	1.6	nc	(nc-nc)
Thyroid				
Male	3	2.7	nc	(nc-nc)
Female	5	8.6	58.4	(18.8-136.3)
Uteri Corpus and Uterus, NOS				
Female	7	9.4	74.6	(29.9-153.7)
All Sites / Types				
Male	129	133.4	96.7	(80.8-114.9)
Female	146	134.5	108.5	(91.6-127.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)
Cervix Uteri				
Female	0	0.1	nc	(nc-nc)
Colon / Rectum				
Male	0	1.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Esophagus				
Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Larynx				
Male	1	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Leukemia				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	1	1.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Ovary				
Female	0	0.3	nc	(nc-nc)
Pancreas				
Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Prostate				
Male	2	3.5	nc	(nc-nc)
Stomach				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Testis				
Male	0	0.2	nc	(nc-nc)
Thyroid				
Male	0	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	0	0.7	nc	(nc-nc)
All Sites / Types				
Male	5	11.7	42.9	(13.8-100.0)
Female	7	9.3	75.5	(30.3-155.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	8	6.1	130.5	(56.2-257.2)
Cervix Uteri				
Female	0	0.2	nc	(nc-nc)
Colon / Rectum				
Male	2	1.5	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)
Esophagus				
Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	0.8	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)
Larynx				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	0.5	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	4	2.5	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Multiple Myeloma				
Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Ovary				
Female	1	0.6	nc	(nc-nc)
Pancreas				
Male	0	0.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Prostate				
Male	6	5.7	105.4	(38.5-229.5)
Stomach				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	0	0.1	nc	(nc-nc)
Thyroid				
Male	0	0.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	1.4	nc	(nc-nc)
All Sites / Types				
Male	18	18.7	96.4	(57.1-152.3)
Female	21	21.2	99.2	(61.4-151.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	7	6.0	117.0	(46.9-241.0)
Cervix Uteri				
Female	1	0.3	nc	(nc-nc)
Colon / Rectum				
Male	2	2.3	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Esophagus				
Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Larynx				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	0	3.3	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Ovary				
Female	1	0.5	nc	(nc-nc)
Pancreas				
Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Prostate				
Male	5	7.2	69.2	(22.3-161.5)
Stomach				
Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	0	0.3	nc	(nc-nc)
Thyroid				
Male	0	0.5	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	4	1.3	nc	(nc-nc)
All Sites / Types				
Male	11	25.6	43.0	(21.4-76.9)
Female	20	18.9	105.7	(64.5-163.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	62	54.6	113.5	(87.0-145.6)
Female	26	22.2	117.2	(76.6-171.8)
Brain and Other Nervous System				
Male	14	9.6	145.9	(79.7-244.8)
Female	8	9.1	87.8	(37.8-172.9)
Breast				
Male	1	1.7	nc	(nc-nc)
Female	208	207.8	100.1	(86.9-114.7)
Cervix Uteri				
Female	13	7.2	179.4	(95.4-306.8)
Colon / Rectum				
Male	77	62.0	124.1	(98.0-155.1)
Female	89	72.3	123.1	(98.8-151.4)
Esophagus				
Male	23	14.0	164.7	(104.4-247.2)
Female	3	4.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	4	3.8	nc	(nc-nc)
Female	1	3.6	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	32	27.5	116.2	(79.5-164.0)
Female	14	17.8	78.7	(43.0-132.0)
Larynx				
Male	9	8.0	112.1	(51.2-212.9)
Female	4	2.6	nc	(nc-nc)
Leukemia				
Male	23	19.7	117.0	(74.1-175.6)
Female	12	16.6	72.5	(37.4-126.6)
Liver and Intrahepatic Bile Ducts				
Male	20	15.9	125.9	(76.9-194.5)
Female	6	6.1	97.6	(35.6-212.5)
Lung and Bronchus				
Male	112	98.4	113.8	(93.7-136.9)
Female	143	112.1	127.6	(107.5-150.3)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	32	34.1	93.8	(64.2-132.5)
Female	38	28.8	132.0	(93.4-181.2)
Multiple Myeloma				
Male	11	9.2	119.1	(59.4-213.2)
Female	5	8.3	60.0	(19.3-140.1)
Non-Hodgkin Lymphoma				
Male	35	30.1	116.4	(81.1-161.9)
Female	30	28.1	106.6	(71.9-152.2)
Oral Cavity & Pharynx				
Male	28	21.0	133.1	(88.4-192.4)
Female	6	11.0	54.7	(20.0-119.2)
Ovary				
Female	15	19.6	76.6	(42.8-126.3)
Pancreas				
Male	19	17.5	108.6	(65.4-169.6)
Female	20	22.0	90.8	(55.4-140.2)
Prostate				
Male	204	198.0	103.0	(89.4-118.2)
Stomach				
Male	8	12.4	64.4	(27.7-126.9)
Female	6	8.8	68.1	(24.9-148.3)
Testis				
Male	8	5.7	140.3	(60.4-276.4)
Thyroid				
Male	16	10.8	147.9	(84.5-240.1)
Female	33	34.7	95.2	(65.5-133.7)
Uteri Corpus and Uterus, NOS				
Female	46	47.6	96.7	(70.8-129.0)
All Sites / Types				
Male	787	708.7	111.0	(103.4-119.1)
Female	798	753.7	105.9	(98.7-113.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)
Cervix Uteri				
Female	0	0.1	nc	(nc-nc)
Colon / Rectum				
Male	0	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Esophagus				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Larynx				
Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Leukemia				
Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	6	2.2	275.1	(100.5-598.8)
Female	2	1.3	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	2	0.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Ovary				
Female	0	0.3	nc	(nc-nc)
Pancreas				
Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Prostate				
Male	1	4.8	nc	(nc-nc)
Stomach				
Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Testis				
Male	0	0.1	nc	(nc-nc)
Thyroid				
Male	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	1	0.7	nc	(nc-nc)
All Sites / Types				
Male	17	15.7	108.4	(63.1-173.5)
Female	8	9.5	83.9	(36.1-165.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	9	7.4	121.6	(55.5-230.9)
Female	4	3.0	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	1.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	27	33.1	81.6	(53.8-118.8)
Cervix Uteri				
Female	1	1.3	nc	(nc-nc)
Colon / Rectum				
Male	3	9.0	nc	(nc-nc)
Female	8	9.6	83.2	(35.8-164.0)
Esophagus				
Male	1	2.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	3	4.3	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)
Larynx				
Male	3	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Leukemia				
Male	6	2.9	208.9	(76.3-454.7)
Female	2	2.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	2.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Lung and Bronchus				
Male	15	13.9	108.0	(60.4-178.2)
Female	19	16.0	118.9	(71.6-185.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	3	5.2	nc	(nc-nc)
Female	5	4.5	110.0	(35.4-256.7)
Multiple Myeloma				
Male	1	1.3	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	8	4.5	178.0	(76.6-350.8)
Female	5	4.0	124.2	(40.0-289.8)
Oral Cavity & Pharynx				
Male	7	3.4	208.3	(83.4-429.1)
Female	3	1.6	nc	(nc-nc)
Ovary				
Female	4	3.0	nc	(nc-nc)
Pancreas				
Male	4	2.5	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)
Prostate				
Male	36	30.2	119.3	(83.6-165.2)
Stomach				
Male	2	1.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Testis				
Male	1	1.1	nc	(nc-nc)
Thyroid				
Male	6	1.9	321.6	(117.4-700.0)
Female	4	6.3	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	8	7.6	105.6	(45.5-208.1)
All Sites / Types				
Male	121	105.0	115.3	(95.6-137.7)
Female	112	112.7	99.4	(81.8-119.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	67	55.2	121.5	(94.1-154.2)
Female	21	21.0	100.1	(61.9-153.0)
Brain and Other Nervous System				
Male	7	11.7	59.9	(24.0-123.4)
Female	11	9.8	112.3	(56.0-201.0)
Breast				
Male	1	1.8	nc	(nc-nc)
Female	289	227.9	126.8	(112.6-142.3)
Cervix Uteri				
Female	6	8.7	68.8	(25.1-149.9)
Colon / Rectum				
Male	79	67.4	117.3	(92.8-146.1)
Female	82	69.0	118.9	(94.5-147.5)
Esophagus				
Male	20	16.0	124.6	(76.1-192.5)
Female	2	4.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	4	5.2	nc	(nc-nc)
Female	8	4.1	196.8	(84.7-387.8)
Kidney & Renal Pelvis				
Male	33	32.9	100.3	(69.0-140.9)
Female	21	18.5	113.8	(70.4-174.0)
Larynx				
Male	14	9.3	149.9	(81.9-251.5)
Female	1	2.8	nc	(nc-nc)
Leukemia				
Male	26	21.4	121.3	(79.2-177.7)
Female	24	16.6	144.7	(92.7-215.3)
Liver and Intrahepatic Bile Ducts				
Male	19	18.8	101.1	(60.9-157.9)
Female	5	6.1	81.5	(26.2-190.1)
Lung and Bronchus				
Male	103	104.3	98.7	(80.6-119.7)
Female	120	108.9	110.2	(91.4-131.8)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	61	39.2	155.7	(119.1-200.1)
Female	61	31.5	193.9	(148.3-249.1)
Multiple Myeloma				
Male	14	10.0	140.2	(76.6-235.2)
Female	6	8.1	74.2	(27.1-161.4)
Non-Hodgkin Lymphoma				
Male	29	33.9	85.5	(57.2-122.8)
Female	40	28.1	142.2	(101.6-193.6)
Oral Cavity & Pharynx				
Male	34	26.2	129.8	(89.9-181.4)
Female	15	11.5	130.8	(73.1-215.7)
Ovary				
Female	22	21.0	105.0	(65.8-159.0)
Pancreas				
Male	17	18.6	91.5	(53.3-146.5)
Female	18	20.7	87.2	(51.6-137.8)
Prostate				
Male	288	239.6	120.2	(106.7-134.9)
Stomach				
Male	17	13.4	126.6	(73.7-202.7)
Female	8	8.2	97.2	(41.9-191.6)
Testis				
Male	6	8.6	69.9	(25.5-152.2)
Thyroid				
Male	16	14.3	111.6	(63.8-181.3)
Female	51	42.4	120.2	(89.5-158.0)
Uteri Corpus and Uterus, NOS				
Female	52	52.7	98.7	(73.7-129.4)
All Sites / Types				
Male	913	805.5	113.3	(106.1-120.9)
Female	935	782.8	119.4	(111.9-127.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	4	2.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	8	11.1	71.8	(30.9-141.5)
Cervix Uteri				
Female	2	0.4	nc	(nc-nc)
Colon / Rectum				
Male	3	3.3	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)
Esophagus				
Male	3	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	2	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Larynx				
Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	1.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Lung and Bronchus				
Male	2	5.3	nc	(nc-nc)
Female	9	4.7	193.0	(88.1-366.5)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	4	1.9	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)
Multiple Myeloma				
Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	1.6	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Ovary				
Female	0	1.0	nc	(nc-nc)
Pancreas				
Male	2	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Prostate				
Male	14	12.5	111.9	(61.1-187.8)
Stomach				
Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Testis				
Male	2	0.4	nc	(nc-nc)
Thyroid				
Male	1	0.7	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	3	2.6	nc	(nc-nc)
All Sites / Types				
Male	43	40.3	106.7	(77.2-143.7)
Female	32	35.7	89.5	(61.2-126.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	2	3.7	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	15	14.1	106.0	(59.3-174.9)
Cervix Uteri				
Female	1	0.6	nc	(nc-nc)
Colon / Rectum				
Male	2	4.7	nc	(nc-nc)
Female	1	3.6	nc	(nc-nc)
Esophagus				
Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	2	2.4	nc	(nc-nc)
Female	4	1.1	nc	(nc-nc)
Larynx				
Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	2	1.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Lung and Bronchus				
Male	4	7.4	nc	(nc-nc)
Female	2	5.8	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	3	2.7	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	2.3	nc	(nc-nc)
Female	4	1.5	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	2.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Ovary				
Female	2	1.2	nc	(nc-nc)
Pancreas				
Male	1	1.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Prostate				
Male	22	18.1	121.4	(76.1-183.9)
Stomach				
Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Testis				
Male	1	0.4	nc	(nc-nc)
Thyroid				
Male	2	1.0	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	3	3.3	nc	(nc-nc)
All Sites / Types				
Male	47	57.4	81.9	(60.2-108.9)
Female	48	44.9	106.9	(78.8-141.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	6	4.9	123.0	(44.9-267.6)
Female	1	1.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	1.0	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	21	16.4	128.3	(79.4-196.1)
Cervix Uteri				
Female	1	0.6	nc	(nc-nc)
Colon / Rectum				
Male	12	6.3	189.2	(97.7-330.5)
Female	3	5.4	nc	(nc-nc)
Esophagus				
Male	3	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	3.2	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)
Larynx				
Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	0	1.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	6	1.9	309.6	(113.0-673.8)
Female	1	0.5	nc	(nc-nc)
Lung and Bronchus				
Male	13	9.5	136.4	(72.5-233.2)
Female	12	8.4	143.3	(74.0-250.4)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	9	3.7	245.4	(112.0-465.9)
Female	4	2.2	nc	(nc-nc)
Multiple Myeloma				
Male	2	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	6	3.1	192.1	(70.2-418.2)
Female	1	2.1	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	4	2.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Ovary				
Female	3	1.5	nc	(nc-nc)
Pancreas				
Male	1	1.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)
Prostate				
Male	18	23.4	76.8	(45.5-121.4)
Stomach				
Male	1	1.2	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)
Testis				
Male	0	0.6	nc	(nc-nc)
Thyroid				
Male	0	1.4	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	6	3.8	156.8	(57.3-341.4)
All Sites / Types				
Male	98	75.6	129.6	(105.2-158.0)
Female	61	57.4	106.3	(81.3-136.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	89	96.2	92.6	(74.3-113.9)
Female	42	40.5	103.7	(74.8-140.2)
Brain and Other Nervous System				
Male	16	18.6	86.0	(49.1-139.6)
Female	10	17.6	56.9	(27.2-104.6)
Breast				
Male	2	3.0	nc	(nc-nc)
Female	360	397.8	90.5	(81.4-100.3)
Cervix Uteri				
Female	19	15.2	124.9	(75.1-195.0)
Colon / Rectum				
Male	136	111.7	121.8	(102.2-144.0)
Female	151	132.8	113.7	(96.3-133.4)
Esophagus				
Male	32	25.6	125.0	(85.5-176.5)
Female	13	8.5	153.5	(81.7-262.6)
Hodgkin Lymphoma				
Male	6	8.7	69.0	(25.2-150.1)
Female	7	7.6	92.2	(36.9-190.0)
Kidney & Renal Pelvis				
Male	59	51.9	113.8	(86.6-146.8)
Female	33	33.6	98.4	(67.7-138.1)
Larynx				
Male	19	14.8	128.4	(77.3-200.5)
Female	6	4.9	122.8	(44.8-267.3)
Leukemia				
Male	28	35.7	78.5	(52.2-113.5)
Female	33	30.9	106.8	(73.5-150.0)
Liver and Intrahepatic Bile Ducts				
Male	59	29.6	199.7	(152.0-257.5)
Female	12	11.4	105.5	(54.5-184.3)
Lung and Bronchus				
Male	200	175.7	113.8	(98.6-130.7)
Female	250	206.0	121.4	(106.8-137.4)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	60	64.2	93.4	(71.3-120.2)
Female	65	57.1	113.9	(87.9-145.1)
Multiple Myeloma				
Male	16	16.7	95.8	(54.7-155.7)
Female	10	15.3	65.4	(31.3-120.2)
Non-Hodgkin Lymphoma				
Male	45	56.0	80.3	(58.6-107.4)
Female	65	52.6	123.6	(95.4-157.5)
Oral Cavity & Pharynx				
Male	61	39.9	152.7	(116.8-196.2)
Female	23	20.7	111.0	(70.3-166.5)
Ovary				
Female	41	37.4	109.8	(78.8-148.9)
Pancreas				
Male	32	31.2	102.6	(70.2-144.8)
Female	40	40.1	99.7	(71.2-135.8)
Prostate				
Male	322	366.9	87.8	(78.4-97.9)
Stomach				
Male	30	22.4	133.9	(90.3-191.1)
Female	14	16.1	86.9	(47.5-145.9)
Testis				
Male	9	15.0	59.9	(27.3-113.7)
Thyroid				
Male	14	22.3	62.7	(34.2-105.2)
Female	80	74.0	108.1	(85.7-134.6)
Uteri Corpus and Uterus, NOS				
Female	100	90.6	110.3	(89.8-134.2)
All Sites / Types				
Male	1335	1304.8	102.3	(96.9-108.0)
Female	1495	1426.7	104.8	(99.5-110.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	25	31.0	80.7	(52.2-119.1)
Female	8	12.2	65.3	(28.1-128.7)
Brain and Other Nervous System				
Male	7	6.2	112.6	(45.1-232.1)
Female	5	5.8	86.4	(27.8-201.5)
Breast				
Male	1	1.0	nc	(nc-nc)
Female	118	132.7	88.9	(73.6-106.5)
Cervix Uteri				
Female	7	5.2	134.5	(53.9-277.1)
Colon / Rectum				
Male	40	37.2	107.7	(76.9-146.6)
Female	41	40.3	101.8	(73.1-138.2)
Esophagus				
Male	7	8.2	85.2	(34.1-175.6)
Female	3	2.6	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	2.8	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	22	17.0	129.5	(81.1-196.1)
Female	9	10.8	83.2	(38.0-158.0)
Larynx				
Male	7	4.7	147.6	(59.1-304.1)
Female	1	1.6	nc	(nc-nc)
Leukemia				
Male	10	11.9	84.2	(40.3-154.9)
Female	7	9.7	71.9	(28.8-148.1)
Liver and Intrahepatic Bile Ducts				
Male	14	9.7	144.8	(79.1-242.9)
Female	6	3.6	167.5	(61.2-364.6)
Lung and Bronchus				
Male	68	55.9	121.6	(94.4-154.1)
Female	66	63.9	103.2	(79.8-131.4)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	16	20.9	76.5	(43.7-124.2)
Female	21	18.6	112.7	(69.7-172.2)
Multiple Myeloma				
Male	5	5.4	92.2	(29.7-215.1)
Female	6	4.7	127.3	(46.5-277.0)
Non-Hodgkin Lymphoma				
Male	20	18.4	108.7	(66.4-167.9)
Female	19	16.5	115.3	(69.4-180.1)
Oral Cavity & Pharynx				
Male	8	13.3	60.1	(25.9-118.4)
Female	6	6.7	90.0	(32.8-195.8)
Ovary				
Female	13	12.2	106.8	(56.8-182.7)
Pancreas				
Male	15	10.1	148.3	(82.9-244.5)
Female	16	12.0	132.8	(75.9-215.7)
Prostate				
Male	113	116.5	97.0	(79.9-116.6)
Stomach				
Male	2	7.3	nc	(nc-nc)
Female	9	4.8	187.4	(85.5-355.8)
Testis				
Male	0	4.7	nc	(nc-nc)
Thyroid				
Male	6	7.4	81.0	(29.6-176.2)
Female	26	25.5	101.8	(66.5-149.2)
Uteri Corpus and Uterus, NOS				
Female	29	30.3	95.6	(64.0-137.3)
All Sites / Types				
Male	425	422.1	100.7	(91.4-110.7)
Female	451	458.1	98.5	(89.6-108.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	16	14.3	111.7	(63.8-181.4)
Female	4	5.1	nc	(nc-nc)
Brain and Other Nervous System				
Male	2	2.8	nc	(nc-nc)
Female	5	2.4	207.0	(66.7-483.1)
Breast				
Male	0	0.5	nc	(nc-nc)
Female	51	56.3	90.6	(67.5-119.2)
Cervix Uteri				
Female	4	2.2	nc	(nc-nc)
Colon / Rectum				
Male	15	17.0	88.2	(49.3-145.5)
Female	16	16.9	94.7	(54.1-153.9)
Esophagus				
Male	4	3.9	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	1.1	nc	(nc-nc)
Female	4	1.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	12	8.0	150.3	(77.6-262.6)
Female	7	4.6	153.5	(61.5-316.4)
Larynx				
Male	1	2.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Leukemia				
Male	6	5.4	110.1	(40.2-239.7)
Female	4	4.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	4	4.6	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)
Lung and Bronchus				
Male	32	26.6	120.4	(82.3-169.9)
Female	34	27.0	126.1	(87.3-176.3)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	9	9.6	93.4	(42.6-177.3)
Female	7	7.8	90.3	(36.2-186.1)
Multiple Myeloma				
Male	2	2.5	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	7	8.4	83.5	(33.5-172.1)
Female	6	6.9	86.7	(31.7-188.8)
Oral Cavity & Pharynx				
Male	6	6.3	95.9	(35.0-208.8)
Female	2	2.8	nc	(nc-nc)
Ovary				
Female	3	5.1	nc	(nc-nc)
Pancreas				
Male	6	4.8	126.2	(46.1-274.7)
Female	1	5.1	nc	(nc-nc)
Prostate				
Male	60	57.0	105.3	(80.3-135.5)
Stomach				
Male	4	3.4	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)
Testis				
Male	6	1.9	323.3	(118.1-703.8)
Thyroid				
Male	5	3.3	149.9	(48.3-349.7)
Female	16	10.5	151.8	(86.7-246.5)
Uteri Corpus and Uterus, NOS				
Female	12	12.9	93.0	(48.0-162.4)
All Sites / Types				
Male	214	198.3	107.9	(94.0-123.4)
Female	204	192.8	105.8	(91.8-121.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	28	25.5	109.9	(73.0-158.9)
Female	12	9.9	121.3	(62.6-211.9)
Brain and Other Nervous System				
Male	6	4.9	121.3	(44.3-264.0)
Female	5	4.5	111.7	(36.0-260.7)
Breast				
Male	0	0.8	nc	(nc-nc)
Female	136	104.5	130.1	(109.2-153.9)
Cervix Uteri				
Female	2	3.9	nc	(nc-nc)
Colon / Rectum				
Male	35	30.0	116.7	(81.3-162.4)
Female	45	32.6	138.1	(100.7-184.7)
Esophagus				
Male	8	6.9	116.7	(50.3-230.0)
Female	3	2.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	2.0	nc	(nc-nc)
Female	5	1.8	284.3	(91.6-663.4)
Kidney & Renal Pelvis				
Male	12	14.0	85.5	(44.1-149.3)
Female	3	8.6	nc	(nc-nc)
Larynx				
Male	4	4.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
Leukemia				
Male	11	9.4	116.5	(58.1-208.5)
Female	14	7.7	180.8	(98.7-303.3)
Liver and Intrahepatic Bile Ducts				
Male	2	8.0	nc	(nc-nc)
Female	5	2.9	174.6	(56.3-407.5)
Lung and Bronchus				
Male	47	47.5	99.0	(72.8-131.7)
Female	50	51.2	97.6	(72.5-128.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	25	16.9	147.9	(95.7-218.4)
Female	19	14.3	133.3	(80.2-208.2)
Multiple Myeloma				
Male	2	4.4	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	15	15.0	100.3	(56.1-165.5)
Female	12	13.1	91.7	(47.3-160.3)
Oral Cavity & Pharynx				
Male	6	10.8	55.5	(20.3-120.8)
Female	4	5.3	nc	(nc-nc)
Ovary				
Female	4	9.6	nc	(nc-nc)
Pancreas				
Male	8	8.3	96.4	(41.5-190.0)
Female	9	9.8	92.1	(42.0-174.9)
Prostate				
Male	85	98.5	86.3	(68.9-106.7)
Stomach				
Male	9	6.0	150.8	(68.8-286.2)
Female	5	3.9	128.0	(41.3-298.7)
Testis				
Male	2	3.0	nc	(nc-nc)
Thyroid				
Male	9	5.8	156.1	(71.2-296.3)
Female	31	18.8	164.9	(112.0-234.0)
Uteri Corpus and Uterus, NOS				
Female	32	23.7	134.8	(92.2-190.3)
All Sites / Types				
Male	340	347.6	97.8	(87.7-108.8)
Female	435	361.7	120.3	(109.2-132.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	11	11.9	92.4	(46.0-165.3)
Female	3	3.7	nc	(nc-nc)
Brain and Other Nervous System				
Male	3	2.5	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	43	46.2	93.1	(67.4-125.4)
Cervix Uteri				
Female	0	1.8	nc	(nc-nc)
Colon / Rectum				
Male	12	14.9	80.7	(41.6-141.0)
Female	11	12.3	89.6	(44.7-160.4)
Esophagus				
Male	1	3.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.0	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	8	7.3	109.5	(47.1-215.7)
Female	4	3.6	nc	(nc-nc)
Larynx				
Male	2	2.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Leukemia				
Male	2	4.6	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	4	4.3	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)
Lung and Bronchus				
Male	22	22.7	96.8	(60.6-146.5)
Female	19	20.1	94.4	(56.8-147.4)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	10	8.5	117.1	(56.1-215.4)
Female	4	6.2	nc	(nc-nc)
Multiple Myeloma				
Male	2	2.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	5	7.4	67.4	(21.7-157.3)
Female	7	5.2	134.1	(53.7-276.3)
Oral Cavity & Pharynx				
Male	3	6.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)
Ovary				
Female	1	4.1	nc	(nc-nc)
Pancreas				
Male	5	4.1	123.0	(39.6-287.1)
Female	5	3.6	138.7	(44.7-323.7)
Prostate				
Male	53	52.8	100.4	(75.2-131.4)
Stomach				
Male	0	2.9	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
Testis				
Male	0	1.6	nc	(nc-nc)
Thyroid				
Male	1	3.1	nc	(nc-nc)
Female	4	9.0	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	10	10.6	94.1	(45.1-173.1)
All Sites / Types				
Male	150	176.3	85.1	(72.0-99.9)
Female	128	150.7	84.9	(70.8-101.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	43	60.5	71.0	(51.4-95.7)
Female	22	20.4	108.0	(67.7-163.5)
Brain and Other Nervous System				
Male	12	10.9	109.8	(56.7-191.8)
Female	9	9.0	99.5	(45.4-189.0)
Breast				
Male	1	1.8	nc	(nc-nc)
Female	223	200.3	111.3	(97.2-127.0)
Cervix Uteri				
Female	8	7.7	103.8	(44.7-204.6)
Colon / Rectum				
Male	77	68.4	112.5	(88.8-140.6)
Female	48	66.9	71.8	(52.9-95.2)
Esophagus				
Male	8	15.1	53.0	(22.8-104.5)
Female	4	4.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	7	4.7	148.1	(59.4-305.3)
Female	2	3.8	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	37	30.1	122.7	(86.4-169.2)
Female	40	17.0	235.7	(168.4-321.0)
Larynx				
Male	16	8.7	184.2	(105.2-299.1)
Female	6	2.5	244.1	(89.1-531.4)
Leukemia				
Male	25	22.2	112.8	(73.0-166.5)
Female	13	15.9	81.9	(43.6-140.1)
Liver and Intrahepatic Bile Ducts				
Male	29	16.9	171.2	(114.6-245.9)
Female	7	5.7	122.0	(48.9-251.4)
Lung and Bronchus				
Male	122	107.3	113.7	(94.4-135.7)
Female	150	104.0	144.3	(122.1-169.3)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	26	38.0	68.4	(44.7-100.2)
Female	31	28.7	107.9	(73.3-153.2)
Multiple Myeloma				
Male	9	10.2	88.4	(40.3-167.8)
Female	9	7.7	116.9	(53.3-221.9)
Non-Hodgkin Lymphoma				
Male	30	33.6	89.2	(60.2-127.3)
Female	32	26.5	120.7	(82.5-170.4)
Oral Cavity & Pharynx				
Male	22	22.6	97.4	(61.0-147.5)
Female	11	10.4	105.6	(52.7-189.0)
Ovary				
Female	17	18.8	90.5	(52.7-144.9)
Pancreas				
Male	16	19.1	83.7	(47.8-135.9)
Female	14	20.2	69.3	(37.9-116.3)
Prostate				
Male	129	212.0	60.9	(50.8-72.3)
Stomach				
Male	15	13.8	108.7	(60.8-179.3)
Female	9	8.1	111.0	(50.7-210.7)
Testis				
Male	9	8.0	113.0	(51.6-214.5)
Thyroid				
Male	13	12.3	105.5	(56.1-180.4)
Female	39	37.3	104.6	(74.3-142.9)
Uteri Corpus and Uterus, NOS				
Female	36	45.4	79.4	(55.6-109.9)
All Sites / Types				
Male	702	778.4	90.2	(83.6-97.1)
Female	795	719.2	110.5	(103.0-118.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	3.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	8	8.4	95.8	(41.3-188.8)
Cervix Uteri				
Female	0	0.3	nc	(nc-nc)
Colon / Rectum				
Male	3	3.6	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)
Esophagus				
Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	1.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Larynx				
Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	1	6.1	nc	(nc-nc)
Female	2	4.1	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	2	2.0	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Multiple Myeloma				
Male	2	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	2	1.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Ovary				
Female	0	0.8	nc	(nc-nc)
Pancreas				
Male	2	1.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Prostate				
Male	20	13.5	147.9	(90.3-228.4)
Stomach				
Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Testis				
Male	0	0.2	nc	(nc-nc)
Thyroid				
Male	0	0.6	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	1	2.0	nc	(nc-nc)
All Sites / Types				
Male	38	43.7	86.9	(61.5-119.3)
Female	23	28.1	81.7	(51.8-122.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	5	5.5	91.5	(29.5-213.4)
Female	2	1.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	1.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	26	20.7	125.8	(82.2-184.4)
Cervix Uteri				
Female	2	0.8	nc	(nc-nc)
Colon / Rectum				
Male	4	6.7	nc	(nc-nc)
Female	2	5.3	nc	(nc-nc)
Esophagus				
Male	1	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	3.3	nc	(nc-nc)
Female	4	1.6	nc	(nc-nc)
Larynx				
Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	1	2.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Lung and Bronchus				
Male	10	10.5	94.8	(45.4-174.4)
Female	3	8.7	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	3	3.9	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)
Multiple Myeloma				
Male	0	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	2	3.3	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	2.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Ovary				
Female	1	1.8	nc	(nc-nc)
Pancreas				
Male	0	1.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)
Prostate				
Male	28	25.3	110.7	(73.6-160.0)
Stomach				
Male	0	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Testis				
Male	1	0.7	nc	(nc-nc)
Thyroid				
Male	3	1.4	nc	(nc-nc)
Female	2	4.1	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	3	4.7	nc	(nc-nc)
All Sites / Types				
Male	65	81.8	79.5	(61.3-101.3)
Female	58	66.6	87.1	(66.2-112.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	25	17.5	142.5	(92.2-210.4)
Female	10	7.0	143.6	(68.8-264.1)
Brain and Other Nervous System				
Male	5	3.6	138.3	(44.6-322.8)
Female	4	3.2	nc	(nc-nc)
Breast				
Male	2	0.5	nc	(nc-nc)
Female	67	74.2	90.3	(70.0-114.7)
Cervix Uteri				
Female	2	2.8	nc	(nc-nc)
Colon / Rectum				
Male	25	20.6	121.6	(78.7-179.5)
Female	28	22.7	123.5	(82.0-178.5)
Esophagus				
Male	11	4.6	238.0	(118.7-425.9)
Female	1	1.5	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.7	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	17	9.5	179.6	(104.6-287.6)
Female	7	6.1	114.4	(45.8-235.7)
Larynx				
Male	4	2.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Leukemia				
Male	15	6.7	222.4	(124.4-366.9)
Female	7	5.5	127.3	(51.0-262.3)
Liver and Intrahepatic Bile Ducts				
Male	3	5.5	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)
Lung and Bronchus				
Male	42	32.1	130.7	(94.2-176.7)
Female	58	36.7	157.9	(119.9-204.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	11	11.8	93.2	(46.5-166.7)
Female	14	10.3	135.6	(74.1-227.5)
Multiple Myeloma				
Male	1	3.1	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	12	10.4	115.8	(59.8-202.4)
Female	9	9.3	96.8	(44.2-183.8)
Oral Cavity & Pharynx				
Male	7	7.3	96.0	(38.5-197.9)
Female	8	3.7	213.9	(92.1-421.6)
Ovary				
Female	4	6.8	nc	(nc-nc)
Pancreas				
Male	7	5.7	122.9	(49.2-253.3)
Female	9	6.9	131.4	(59.9-249.4)
Prostate				
Male	72	66.0	109.1	(85.4-137.4)
Stomach				
Male	2	4.1	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)
Testis				
Male	3	2.9	nc	(nc-nc)
Thyroid				
Male	3	4.1	nc	(nc-nc)
Female	20	13.8	144.4	(88.2-223.0)
Uteri Corpus and Uterus, NOS				
Female	15	17.0	88.1	(49.2-145.2)
All Sites / Types				
Male	295	238.6	123.6	(109.9-138.6)
Female	291	257.4	113.1	(100.4-126.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	18	12.4	145.3	(86.1-229.6)
Female	7	4.5	155.8	(62.4-321.0)
Brain and Other Nervous System				
Male	2	2.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Breast				
Male	2	0.4	nc	(nc-nc)
Female	39	42.9	91.0	(64.7-124.4)
Cervix Uteri				
Female	0	1.4	nc	(nc-nc)
Colon / Rectum				
Male	19	14.0	135.8	(81.7-212.1)
Female	15	14.5	103.2	(57.7-170.2)
Esophagus				
Male	6	3.2	189.1	(69.0-411.6)
Female	1	0.9	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	3	6.0	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)
Larynx				
Male	1	1.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Leukemia				
Male	8	4.3	185.0	(79.7-364.6)
Female	1	3.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	3.7	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Lung and Bronchus				
Male	19	22.0	86.4	(52.0-134.9)
Female	14	22.9	61.1	(33.4-102.5)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	8	7.4	107.6	(46.3-212.0)
Female	8	5.6	141.8	(61.1-279.5)
Multiple Myeloma				
Male	1	2.1	nc	(nc-nc)
Female	4	1.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	8	6.6	121.4	(52.3-239.2)
Female	6	5.7	105.8	(38.6-230.4)
Oral Cavity & Pharynx				
Male	6	4.7	126.8	(46.3-275.9)
Female	4	2.2	nc	(nc-nc)
Ovary				
Female	2	4.0	nc	(nc-nc)
Pancreas				
Male	4	4.0	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)
Prostate				
Male	40	44.9	89.2	(63.7-121.4)
Stomach				
Male	1	2.8	nc	(nc-nc)
Female	4	1.8	nc	(nc-nc)
Testis				
Male	2	0.9	nc	(nc-nc)
Thyroid				
Male	2	2.2	nc	(nc-nc)
Female	7	6.5	107.1	(42.9-220.7)
Uteri Corpus and Uterus, NOS				
Female	11	10.1	109.4	(54.5-195.7)
All Sites / Types				
Male	164	158.1	103.7	(88.5-120.9)
Female	146	152.7	95.6	(80.7-112.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)
Cervix Uteri				
Female	0	0.1	nc	(nc-nc)
Colon / Rectum				
Male	0	1.0	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Esophagus				
Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Larynx				
Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Leukemia				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	1	1.7	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	2	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Ovary				
Female	0	0.2	nc	(nc-nc)
Pancreas				
Male	0	0.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)
Prostate				
Male	2	3.3	nc	(nc-nc)
Stomach				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Testis				
Male	0	0.0	nc	(nc-nc)
Thyroid				
Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	0.5	nc	(nc-nc)
All Sites / Types				
Male	9	11.6	77.6	(35.4-147.4)
Female	9	7.2	125.0	(57.0-237.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	9	5.0	180.1	(82.2-341.8)
Female	0	1.9	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	1.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	24	22.9	104.7	(67.1-155.8)
Cervix Uteri				
Female	2	0.9	nc	(nc-nc)
Colon / Rectum				
Male	3	6.6	nc	(nc-nc)
Female	5	6.4	77.5	(25.0-180.9)
Esophagus				
Male	6	1.5	410.3	(149.8-893.1)
Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	3	3.2	nc	(nc-nc)
Female	4	1.8	nc	(nc-nc)
Larynx				
Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Leukemia				
Male	1	2.0	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Lung and Bronchus				
Male	7	9.5	74.1	(29.7-152.6)
Female	9	9.9	90.9	(41.5-172.6)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	3.8	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)
Multiple Myeloma				
Male	0	1.0	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	5	3.3	149.7	(48.3-349.4)
Female	2	2.6	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	4	2.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Ovary				
Female	1	2.1	nc	(nc-nc)
Pancreas				
Male	3	1.7	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)
Prostate				
Male	23	21.1	108.8	(69.0-163.3)
Stomach				
Male	0	1.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Testis				
Male	0	0.8	nc	(nc-nc)
Thyroid				
Male	1	1.5	nc	(nc-nc)
Female	5	4.5	110.8	(35.7-258.6)
Uteri Corpus and Uterus, NOS				
Female	4	5.1	nc	(nc-nc)
All Sites / Types				
Male	70	74.8	93.6	(72.9-118.2)
Female	70	75.7	92.4	(72.0-116.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	1.8	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	5	4.9	102.4	(33.0-239.0)
Cervix Uteri				
Female	0	0.2	nc	(nc-nc)
Colon / Rectum				
Male	3	2.2	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
Esophagus				
Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	1.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Larynx				
Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	3	3.6	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	1.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Ovary				
Female	0	0.4	nc	(nc-nc)
Pancreas				
Male	1	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Prostate				
Male	4	8.6	nc	(nc-nc)
Stomach				
Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	1	0.2	nc	(nc-nc)
Thyroid				
Male	1	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	1.1	nc	(nc-nc)
All Sites / Types				
Male	19	27.1	70.2	(42.2-109.6)
Female	15	16.0	93.9	(52.5-154.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;